Iberogast gets warnings after Bayer concession
This article is powered by OTC Bulletin & The Rose Sheet
Executive Summary
Bayer Consumer Health has after a decade long stalemate with the German Federal Institute for Drugs and Medical Devices, BfArM, conceded to add warnings regarding possible liver damage to the patient information leaflet of its Iberogast gastrointestinal herbal medicine.
You may also be interested in...
Bayer Stands By Iberogast As German Court Investigates Manslaughter Case
Bayer's Iberogast is in the spotlight in Germany. According to media reports, a German court is investigating a 2018 Iberogast-related death as a possible case of manslaughter and bodily harm caused by negligence. Bayer is standing behind its product, stating that the death was “most probably” due to an “idiosyncratic reaction.”
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.